ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1298

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis

Catherine Bingham1, Julia Harris2, Sheetal Vora3, Mileka Gilbert4, Cagri Yildirim-Toruner5, Kerry Ferraro6, Tingting Qiu7, Jon Burnham8, Michelle Batthish9, Beth Gottlieb10, Daniel Lovell7, Ronald Laxer11, Tzielan Lee12, Danielle Bullock13, Charles H Spencer14, Jennifer Weiss15, Melissa Hazen16, Edward Oberle17, Melissa Mannion18, Nancy Pan19, Michael Shishov20, Danielle Fair21, Mary Toth22, Kendra Wiegand7 and Esi Morgan23, 1Penn State Children's Hospital, Hershey, PA, 2Children's Mercy Kansas City, Overland Park, KS, 3Atrium Health Levine Children's, Charlotte, NC, 4Medical University of South Carolina, Charleston, SC, 5Texas Children's Hospital/ Baylor College of Medicine, Houston, TX, 6Pediatric Rheumatology Care and Outcomes Improvement Network, Philadelphia, 7Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Children's Hospital of Philadelphia, Philadelphia, PA, 9McMaster University, Hamilton, ON, Canada, 10Cohen Children's Medical Center, Lake Success, NY, 11Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 12Stanford University School of Medicine, Palo Alto, CA, 13University of Minnesota, Minneapolis, MN, 14Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, 15Hackensack University Medical Center, Hackensack, NJ, 16Boston Children's Hospital, Boston, MA, 17Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 18University of Alabama at Birmingham, Birmingham, AL, 19Hospital for Special Surgery, New York, NY, 20Phoenix Children's Hospital, Phoenix, AZ, 21Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, 22Nemours Foundation, Orlando, FL, 23Seattle Children's Hospital, Seattle, WA

Meeting: ACR Convergence 2022

Keywords: Disease Activity, Juvenile idiopathic arthritis, Outcome measures, Patient reported outcomes, Quality Indicators

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Measures and Measurement of Healthcare Quality Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a Learning Health Network designed to improve outcomes of care for children with juvenile idiopathic arthritis (JIA). Currently, 23 pediatric rheumatology centers in North America participate, and a subset are currently entering data into a network Registry with a goal to report performance on process and outcome quality measures (QMs) to drive improved outcomes.

Methods: PR-COIN centers learn and use established quality improvement (QI) methodology to conduct improvement work. Since 2011, participating sites have entered data from JIA clinical encounters into a shared Registry. Performance on QMs is reported on statistical process control charts for both site-specific and aggregate data to identify significant change in performance, or special cause variation. Disease specific outcome measures include the clinical Juvenile Arthritis Disease Activity Score (cJADAS10), clinically inactive disease (CID), active joint count (AJC), and the time to inactive disease or low disease activity (LDA). Patient-reported outcomes measures (PROMs) include optimal physical function, low or no pain as defined as arthritis pain score < /=3, and patient global assessment of overall well-being (PtGA).

Results: Recent PR-COIN performance data includes 2043 children with JIA, and a total of >8200 children with JIA have been enrolled in the PR-COIN Registry since 2011. Disease activity outcomes have improved over time including mean AJC, mean cJADAS10, percent of patients with oligoarticular or polyarticular JIA who have inactive disease or LDA by cJADAS10, and percent of patients with CID (excluding inflammatory markers) (Figure 1). PROMs have also improved including mean PtGA, percent of patients with PtGA < /= 2, percent of patients with optimal physical function, and percent of patients with low or no pain (Figure 2). Figure 3 illustrates the control chart showing improvement in percentage of patients with PtGA < /=2 from 67% to 75%. Recent data reflects approximately 37% of the patients enrolled in the PR-COIN Registry and currently receiving pediatric rheumatology care at PR-COIN sites.

Conclusion: PR-COIN, a multi-center learning network implementing QI science that utilizes a shared Registry to report QMs and identify best practices, has demonstrated success in improving outcomes for children with JIA. Ongoing analysis of outcome performance will continue as more patients are included in the Registry. Data quality efforts are underway to ensure complete and representative data.

Supporting image 1

Figure 1: Y axis represents mean score (disease activity by cJADAS10 and AJC) and percent of patients who achieve the measure (inactive or LDA, and Clinical Inactive Disease).

Supporting image 2

Figure 2: Y axis represents mean PtGA score and percent of patients who achieve the measure (optimal physical function, no or mild pain, and PtGA

Supporting image 3

Figure 3: Blue dotted line=PR-COIN aggregate performance; Black dotted line=mean; Red dotted lines=control limits (+/_3 standard error of mean)


Disclosures: C. Bingham, None; J. Harris, None; S. Vora, None; M. Gilbert, None; C. Yildirim-Toruner, None; K. Ferraro, None; T. Qiu, None; J. Burnham, None; M. Batthish, None; B. Gottlieb, None; D. Lovell, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKlein(GSK), Novartis, UCB, Bristol-Myers Squibb(BMS), Pfizer, Janssen, NIH/NIAMS, NIH/NICHD, Roche; R. Laxer, Eli Lilly, Novartis, sanofi, sobi; T. Lee, None; D. Bullock, None; C. Spencer, None; J. Weiss, None; M. Hazen, None; E. Oberle, None; M. Mannion, None; N. Pan, None; M. Shishov, None; D. Fair, None; M. Toth, None; K. Wiegand, None; E. Morgan, None.

To cite this abstract in AMA style:

Bingham C, Harris J, Vora S, Gilbert M, Yildirim-Toruner C, Ferraro K, Qiu T, Burnham J, Batthish M, Gottlieb B, Lovell D, Laxer R, Lee T, Bullock D, Spencer C, Weiss J, Hazen M, Oberle E, Mannion M, Pan N, Shishov M, Fair D, Toth M, Wiegand K, Morgan E. Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/pediatric-rheumatology-care-and-outcomes-improvement-network-demonstrates-outcome-improvement-for-children-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pediatric-rheumatology-care-and-outcomes-improvement-network-demonstrates-outcome-improvement-for-children-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology